Production (Stage)
Aldeyra Therapeutics, Inc.
ALDX
$2.22
-$0.03-1.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.00M | 1.95M | 3.70M | 3.04M | 3.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.43M | 16.58M | 16.14M | 18.01M | 9.39M |
| Operating Income | -10.43M | -16.58M | -16.14M | -18.01M | -9.39M |
| Income Before Tax | -9.93M | -15.81M | -15.11M | -16.85M | -8.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.93M | -15.81M | -15.11M | -16.85M | -8.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.93M | -15.81M | -15.11M | -16.85M | -8.08M |
| EBIT | -10.43M | -16.58M | -16.14M | -18.01M | -9.39M |
| EBITDA | -10.37M | -16.51M | -16.07M | -17.95M | -9.33M |
| EPS Basic | -0.17 | -0.27 | -0.25 | -0.28 | -0.14 |
| Normalized Basic EPS | -0.10 | -0.17 | -0.16 | -0.18 | -0.09 |
| EPS Diluted | -0.17 | -0.27 | -0.25 | -0.28 | -0.14 |
| Normalized Diluted EPS | -0.10 | -0.17 | -0.16 | -0.18 | -0.09 |
| Average Basic Shares Outstanding | 59.89M | 59.58M | 59.53M | 59.41M | 59.41M |
| Average Diluted Shares Outstanding | 59.89M | 59.58M | 59.53M | 59.41M | 59.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |